Ymmunobio is a Swiss Biotech Company founded in Basel in 2021 by experienced drug development experts and entrepreneurs, Katrin Rupalla & Peter Schiemann. The Ymmunobio Team is one of the most experienced in the industry with veteran drug development experts on board. Ymmunobio develops a Theranostics platform for treatment of solid tumors based on an invention by Dr. Mitsuro Kanda, School of Medicine, Nagoya University, Japan. The IP belongs completely to Ymmunobio. Founders, OKG Capital and private investors have supported Ymmunobio with CHF 1.7M to date. Ymmunobio’s asset is a First-in-Class TUMOR MARKER with OUTSTANDING PROPERTIES addressing unmet medical need: – Proven Presence in >13 Solid Tumors – Highest Prevalence in Patients up to 98% – Clear Presence in Tumor Tissue Only; No Presence in Normal Tissue 2 ADCs with positive results in vitro and in vivo 2 Radiopharmaceuticals in co-development with PSI* fully supported by Innosuisse 2 Bi-specific T-cell engager antibodies (BiTE) in lead optimization Raising CHF 10M to bring the lead ADC to IND ready stage Exit Scenarios: – IND ready stage including Tox studies and CMC scale up – PoC in humans (dose escalation and expansion cohort/basked trial) Seeking Co-Development partnership with Industry or investor support *PSI: Paul-Scherrer-Institute
Xuxin (HongKong) Biotechnology Co., Limited
Xu Xin (Hong Kong) Biotechnology Co., Ltd. is a high-tech enterprise located in the Hong Kong Science Park, specializing in AI-driven research and development on innovative RNA-targeted therapy. The company is committed to addressing the unmet clinical needs in genetic diseases, neurological disorders, chronic diseases, and other therapeutic areas, and is dedicated to advancing the development of precision medicine through cutting-edge technologies. The company possesses a world-first RNA precision editing technology platform, which includes the world’s largest ADAR substrate editing library, an RNA fragment excising tool, and the AI-driven ATOMIC platform. These breakthrough innovations provide strong support and assurance for the company’s research and development of novel drugs. Through these top-notch technologies, the company is able to overcome the limitations of traditional small-molecule and biologic drugs, and to address key therapeutic challenges such as frameshift mutation diseases, single-point mutation genetic diseases, metabolic diseases and Immuno-oncology diseases. At the same time, our technical strategies ensure to avoid the irreversible off-target safety risks associated with DNA-level gene editing therapies.
Xiaomo Biotech Limited
Xiaomo Biotech is an expert on RNA biosynthesis. Our green biomanufacturing technology produces highly potent, specific, and cost-effective siRNAs (to kilograms) for various RNAi applications including gene knockdown in mammalian cells, high-throughput RNAi screen and RNAi pesticide. Xiaomo is committed to developing cutting-edge biotech products based on RNA interference (RNAi), a natural process which uses small interfering RNAs (siRNAs) to silence target genes in a precise manner. Xiaomo possesses a revolutionary RNAi platform technology known as the ‘prokaryotic siRNA’ (pro-siRNA) technology. The pro-siRNA technology uses bacteria as siRNA ‘factory’ instead of using chemical synthesis. This unique biomanufacturing method enables cost-effective and environmentally friendly production of highly effective siRNAs on a massive scale. Xiaomo has the capacity to produce siRNAs in gram to kilogram scales using bacterial fermentation. Xiaomo has also developed a customized high-throughput RNAi screen technique to identify potential therapeutic target genes in a disease, that could lead to the development of novel RNAi therapeutics. Currently, Xiaomo is offering various biomanufactured siRNA and RNAi library products to the R&D market. Xiaomo’s R&D efforts focus on developing first-in-class RNA pesticides for important crop pests including fungi, insects and nematodes. The ultimate goal of Xiaomo is to provide effective and affordable RNAi solutions for improving both human health and agricultural health. Xiaomo Biotech (www.xiaomobio.com) was founded at Hong Kong Science Park in 2019. We have recently established R&D and production sites in Shanghai Zhangjiang and Suzhou Kunshan China.
WT Faba Biocatalyst LLP
WT Faba Catalyst: Bridging Science and Business in Life Sciences WT Faba Catalyst, a pioneering initiative of the ‘Whale Tank FABA Life Science Fund’, is redefining how Indian innovation in life sciences reaches global markets. Born from the vision of seasoned veterans and mission-driven leaders, it provides not just capital—but clarity, confidence, and capability—to life science startups poised to transform human health, agriculture, and nutrition. With ‘strategic partnerships’ that already include Revelations Biotech’, ‘ATGC Biotech’, and ‘Utopia Therapeutics’, Whale Tank has become a cornerstone of support for startups navigating the demanding path from the lab bench to the marketplace. **Our Origin Story: Built by Experts, For Innovators** Whale Tank was founded by a group of **industry veterans** with a shared mission: **to resolve the systemic challenges faced by deep-science startups** in India and the global South. From their work in pharma, agritech, biotech, and venture capital, these leaders understood a core reality—**innovation alone isn’t enough**. Scientific breakthroughs often stall due to fragmented business planning, unclear market access, and limited investor guidance. To change this narrative, Whale Tank was established as a **science-first catalyst** with business-savvy DNA, offering tailored support to help life sciences ventures scale impact and unlock commercial potential. — ### **Strategic Partnerships that Amplify Innovation** Whale Tank doesn’t just fund ideas—it backs missions. Our growing portfolio features strategic collaborations with: #### **Revelations Biotech** An innovative force in **natural sweeteners and prebiotics**, Revelations is redefining food and nutrition science with cutting-edge products like **Fructooligosaccharides (FOS)**, **Brazzein**, and **Allulose**. Whale Tank invested $2 million in this high-growth venture, facilitating: – Global partnerships with **Kellogg’s**, **PepsiCo**, **Nestlé**, **Britannia**, and **Unilever** – Scale-up of production infrastructure (fermentation and spray-drying facilities) – Market penetration across **North America**, **Europe**, and **Asia-Pacific** Revelations reflects Whale Tank’s belief that **science-driven startups can reshape public health, when supported with strategic capital and mentorship**. #### **ATGC Biotech** As a biotechnology pioneer in **sustainable agriculture and pest management**, ATGC has developed eco-friendly technologies that improve crop yields while minimizing environmental impact. Under the leadership of **Dr. Markandeya Gorantla** and **Rolando Alegria**, ATGC: – Specializes in bio-rational solutions using behavioral ecology using pheromone based mating disruption technology – Has filed multiple patents and gained regulatory approvals – Has scaled distribution through private sector and public procurement models Whale Tank and ATGC share a common DNA: commitment to **science-backed sustainability** and **farm-to-fork innovation**. #### **Utopia Therapeutics** Founded by **Dr. Uday Saxena**, Utopia is a drug discovery and therapeutics startup with a focus on **neurodegenerative and metabolic disorders**. Utopia’s leadership—rooted in big pharma —guides startups in navigating clinical validation, regulatory frameworks. Whale Tank’s synergy with Utopia provides its portfolio companies with strategic insights into **drug development lifecycles**, **FDA compliance**, and **venture pathways. — ### **Mission-Driven Investment Philosophy** At its core, **Whale Tank is a catalyst, not just a fund**. Our mission is to: – **Fuel Innovation** through strategic, milestone-based capital – **Bridge Science and Business** with real-world execution models – **Accelerate Commercialization** across agriculture, biotech, diagnostics, and therapeutics – **Empower Indian Science** by building platforms for global impact We understand that scientific excellence must be matched with **business discipline** and **market readiness**—so we provide both. — ### **Our Values: The Whale Tank Ethos** Our approach is guided by unwavering principles that reflect our commitment to lasting impact: #### Integrity as a Foundation of Trust We uphold the highest standards of transparency and ethical governance, ensuring alignment between founders, investors, and stakeholders. #### Collaboration for Greater Innovation We believe that breakthrough ideas flourish in collaborative ecosystems. Whale Tank connects innovators with world-class mentors, global partners, and technical experts to foster innovation at scale. #### Commitment to Continuous Improvement The life sciences landscape evolves fast—and so do we. From regulatory updates to tech advancements, we equip our portfolio with the latest tools to stay competitive and compliant. — ### **Our Differentiators: The Whale Tank Advantage** Whale Tank delivers a full-spectrum support model that integrates: | Service | Description | |——–|————-| | **Visionary Capital** | Flexible seed and Series A funding, aligned to product-market readiness | | **Mentorship Network** | Access to 50+ domain experts in biotech, drug development, clinical trials, and regulatory science | | **Business Alchemy** | Go-to-market, licensing, pricing, and distribution support | | **IP & Legal Advisory** | End-to-end guidance on patents, exclusivity, and data rights | | **Infrastructure Scaling** | Support for facility design, tech transfer, and manufacturing scale-up | | **Exit Strategy Navigation** | IPO prep, M&A, and secondary share sale pathways | This framework has empowered startups to **reduce time-to-market**, **attract global partners**, and **build sustainable revenue models**. — ### **Governance, Structure & Investor Value** ### **Impact Snapshot: Delivering Results that Matter** Beyond numbers, our true impact is in lives touched, diseases addressed, and ecosystems enhanced. Whether it’s **healthy nutrition**, **sustainable farming**, or **precision medicine**, Whale Tank empowers science that serves society. — ### **Vision for the Future: Scaling Science for Global Good** Whale Tank is now building a **pipeline of next-gen ventures** across: – **Synthetic Biology** – **Microbiome Therapeutics** – **Agricultural Biocontrols** – **Climate-Resilient Crop Technologies** – **Affordable Diagnostics and Functional Foods** Our goal is to create **India’s first science-forward unicorns** that are not just financially successful—but mission-aligned and globally relevant. — ### **Join the Movement: Let’s Build the Future of Life Sciences** We invite researchers, entrepreneurs, and investors to partner with us. Whether you’re developing the next sugar alternative, breakthrough therapy, or agricultural bioinnovation—**Whale Tank will help you get there.** For partnerships and investment inquiries, contact: **Dr. Jagadeesh Gandla** Chief Operating Officer, Whale Tank FABA Life Science Fund **info@whaletank.in** — **WT Faba Catalyst isn’t just a fund. It’s a movement.** A movement to **empower ideas**, **bridge discovery with delivery**, and **build India’s life sciences future**—one transformative startup at a time. Let’s catalyze the change.
Westchester County Office of Economic Development
Life Sciences, including Biotech, Med Devices, Digital Health are a priority sector for Westchester County. The industry is anchored by our homegrown success story, Regeneron, the largest life sciences employer in New York State. There are over 200 other life sciences companies and supporting organizations in our County, as well as a biotech incubator on the campus of New York Medical College, and a County-sponsored competitive entry, life sciences accelerator program that accepts 12 startups per year. The accelerator, WCBA, completes its 2025 cohort in May, and will then have over 70 alumni founders who have completed the program. We welcome conversations with any life sciences company seeking a new home in a supportive environment, minutes from New York City, with ready access to the talent pool and academic resources in our region. We welcome conversations with investors who would like to learn about the rich ecosystem in Westchester. We welcome conversations with CMOs, CDMOs and other organizations that are curious to learn more about the life sciences community in our area, and anyone else looking for collaborations.
Wacker Biotech
WACKER BIOTECH is “THE MICROBIAL CDMO” – your partner of choice for process development and contract manufacturing of biopharmaceuticals (proteins, vaccines, live microbial products, plasmid DNA (pDNA)) using microbial hosts. Additionally, WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation, the nucleic acid expertise of Wacker Biotech combined with the lipid expertise of our partner CordenPharma ensures the best possible results for each of our client’s mRNA-focused projects. WACKER BIOTECH’s integrated service portfolio covers molecular biology, process / analytical development as well as GMP manufacturing of biologics for clinical and commercial supply. WACKER BIOTECH operates four state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands. Manufacturing lines are equipped with stainless steel fermentation vessels from 350 to 1500 liter as well as single-use bioreactors. Matching primary recovery, downstream and Fill & Finish capabilities are available to suit various clients’ needs across the development path (BSL 1 and 2). Additionally, a GMP cell-bank suite enables independent cell-bank production and storage capacity for client cell banks. In 2022 the German government selected Wacker Biotech and CordenPharma as joint bidders for the stand-by production of vaccines based on mRNA. Therefore, WACKER is now building a state-of-the-art mRNA competence and manufacturing center at its existing Halle, Germany site to complement its other existing sites in Jena, Germany, Amsterdam, the Netherlands and San Diego, California. The new capabilities at Wacker Biotech Halle will support end-to-end manufacturing of plasmid DNA, mRNA and LNP formulation under one roof. WACKER BIOTECH holds biomanufacturing certificates from the relevant authorities for all sites and follows the ICH Q7A guidelines for GMP-compliant production of biologics. The GMP production facilities in the Netherlands and Germany are approved by the EMA, U.S. FDA and/or ANVISA for commercial manufacturing. The WACKER BIOTECH U.S. site is currently preparing for a U.S. FDA inspection. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of Munich-based Wacker Chemie AG. | WACKER BIOTECH is the CDMO partner of choice for process development and manufacturing of biopharmaceuticals (therapeutic proteins, vaccines, live biotherapeutic products) based on microbial systems and for the entire manufacturing chain of pDNA, mRNA and lipid nanoparticle formulations. Our clients benefit from our decades of experience in complex protein-based therapeutics, vaccines, and specialty chemicals sectors, including partnering with the German government to respond to the Covid-19 pandemic. WACKER BIOTECH operates five state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands. Manufacturing lines are equipped with stainless steel fermentation vessels from 350 to 1500 liter as well as single-use bioreactors. Matching primary recovery, downstream and Fill & Finish capabilities are available to suit various clients’ needs across the development path (BSL 1 and 2). WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation, the nucleic acid expertise of Wacker Biotech combined with the lipid expertise of our partner ensures the best possible results for each of our client’s mRNA-focused projects. In Amsterdam, NL, we jump-started mRNA manufacturing during the COVID-19 pandemic, making us a leading CDMO with hands-on GMP manufacturing experience of mRNA-based therapies, including validation GMP runs. With the addition of another cutting-edge competence center for mRNA actives in Halle, Germany, we have increased our RNA product manufacturing and LNP formulation capacity. In this dynamic field of advanced therapies, you will benefit from experienced, reputable partners validated by the German government. In close collaboration with universities and research institutions, WACKER’s corporate R&D team of over 200 researchers continuously develops new production platforms and technologies for all types of biopharmaceuticals, including pDNA, mRNA and LNPs. Competitive, outstanding solutions are our trademarks. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of Munich-based Wacker Chemie AG. | Wacker Biotech is the expert biologics CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid and template DNA as a starting material for mRNA through the IVT of mRNA to lipid nanoparticle (LNP) formulation. We have the capability to produce at diverse scales up to 1500 L and recently quadrupled our mRNA production capacity with the completion of a new mRNA competence center in Halle, Germany. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization. We operate five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and the US (San Diego). Complementing our bioprocess development and manufacturing experts at these four sites is a team of dedicated research scientists leading continuous innovations and collaborations at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading chemistry advances. We have 30+ years of experience developing biologics to advance human and animal health. | Wacker Biotech is the expert biologics CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid DNA as a starting material for RNA, to the IVT of RNA, to lipid nanoparticle (LNP) formulation. We also produce >97% supercoiled plasmids for AAV and LV delivery, and for direct application. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization. Our global footprint encompasses five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and USA (San Diego), able to produce at diverse R&D, HQ and GMP grades, with scale-up to 1500 L. Complementing our bioprocess development and manufacturing experts at these sites is a team of dedicated research scientists leading continuous innovations and collaborations, and also providing nucleic acid contract research services, at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading biochemistry advances. We have 30+ years of experience manufacturing biologics to advance human and animal health.
VivoSphere LLC
At VivoSphere, we address a critical industry challenge: the early-stage identification of ineffective or toxic drug candidates to prevent costly failures in clinical trials. With VivoSphere technology, we create more human-like tissue models for more human-like drug responses. By offering three-dimensional tissue-engineered models that mimic human physiological responses more closely than traditional two-dimensional cell cultures, VivoSphere empowers pharmaceutical companies to improve the safety and efficacy of therapeutics, reduce reliance on animal testing, and make more informed decisions faster while reducing costs.
Vipragen Biosciences Private Limited
Vipragen Biosciences Pvt. Ltd. is a CRO certified by NGCMA for OECD-GLP to carry out safety studies for regulatory submissions. Additionally, the laboratory has been certified by AAALAC, NABL, and DCGI to support discovery research. Vipragen has deep scientific and research knowledge with a combined experience of over 150 years of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME. | Vipragen Biosciences Pvt. Ltd. is a globally recognized Contract Research Organization(CRO) which has been in the industry for more than a decade now and specializing in delivering comprehensive pre-clinical services to Global Drug Discovery companies. We are OECD-GLP certified and AAALAC accredited laboratory with the State-of-the-art Vivarium to carry out safety studies for regulatory submissions. Vipragen has deep scientific and research knowledge of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME. | Vipragen, a renowned Contract Research Organization (CRO), offers comprehensive services for global Pharmaceutical, Biopharmaceutical, Chemical, Nutraceutical and Medical Device companies. With over 12 years of experience, Vipragen Biosciences Private Limited is dedicated to delivering quality services. Under the leadership of Dr. Chandrashekaran Siddamadappa, Chairman and Managing Director, Vipragen has emerged as an Integrated Pre-clinical CRO, championing sustainability, integrity, safety and quality. Our state-of-the-art Vivarium holds Global certifications like OECD GLP, AAALAC and NABL, supported by multidisciplinary experts and equipped with 21CFR Part 11 compliance systems and processes. We ensure reliable data adhering to global standards with a focus on customer satisfaction. Our diverse portfolio includes Analytical, Toxicology and Chemistry services tailored to meet stringent regulatory submission requirements across the industries, ensuring compliance and transparency for clients across the industry spectrum.
VIB – FLANDERS INSTITUTE FOR BIOTECHNOLOGY
VIB is an entrepreneurial life sciences institute situated in Flanders, Belgium. Based on a close partnership with five Flemish universities – Ghent University, KU Leuven, University of Antwerp, Vrije Universiteit Brussel and Hasselt University – and supported by a solid funding program from the Flemish government, VIB unites the expertise of all its collaborators and research groups in a single institute. Our institute has an excellent track record in translating basic scientific results into pharmaceutical, agricultural and industrial applications. VIB’s Innovation & Business team currently has a portfolio of +280 patent families. The team executes about 250 partnering agreements with innovative companies on annual basis. Furthermore, VIB Innovation & Business has established 24 VC backed start-up companies, employing +950 staff, over the past 24 years. Our goal for BIO2024 is to partner several opportunities in the fields of neurodegeneration, inflammation, infectious diseases and oncology. Last but not least, VIB has 10 institutional Core Facilities, providing support in a wide array of research fields and housing specialized scientific equipment and services for each discipline (e.g. bioinformatics, proteomics, nanobody production, bioimaging, protein production, spatial transcriptomics, single cell analysis and genomics). These core facilities can offer their services to academic and industrial parties. | VIB is a leading life sciences research institute based in Belgium, renowned for its work in medical sciences, plant biology, microbiology, artificial intelligence and biotechnology. VIB’s mission is to push the boundaries of scientific discovery, transform it into disruptive biotech innovations and support the growth of the life sciences ecosystem in Flanders (Belgium). VIB is a partnership with KU Leuven, Ghent University, University of Antwerp, Vrije Universiteit Brussel, and Hasselt University. VIB drives the translation of research discoveries into innovative products and technologies for patients and society. It does so by launching new spin-offs, licensing intellectual property, engaging in dynamic partnerships and fostering talent development. VIB has created 39 spin-offs in the healthcare and agrifood sectors, attracting over €1.8 billion in equity investment and has partnered intensely with industry, generating over €350 million in income. VIB’s research has led to dozens of innovative products brought to market for medical, agriculture, and food applications, with many more in development. Seven of its spin-off companies have reached the clinical stage. Learn more at www.vib.be.